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most severe patients. chymase levels were higher in patients with narrow pulse pressure and clinical 
warning signs such as severe leakage, fluid accumulation, pleural effusion, gall‑bladder wall thickening 
and rapid haematocrit rise concurrent with thrombocytopenia. no association between chymase and 
liver enlargement was observed. This study confirms that serum chymase levels are associated with 
DHf/Severe dengue disease in hospitalized pediatric patients. chymase levels correlate with warning 
signs of vascular dysfunction highlighting the possible functional role of chymase in vascular leakage 
during dengue.
Dengue virus (DENV) is one of the most important human pathogens and infects between 50 and 390 million 
people each  year1. DENV is now endemic in over 100 countries worldwide and one estimate suggests that ~ 3.9 
billion people are at risk for contracting the  disease2,3. Increasingly, international travelers are also  affected4–7. 
In Sri Lanka (the site for this study), a major outbreak of dengue occurred in 2017, resulting in ~ 185,000 clini-
cal  cases8. The burden of dengue is also high in other Southeast Asian countries including Malaysia, Thailand, 
Vietnam and the Philippines where there were nearly 1,400 DENV-related deaths reported in 2017  alone9. DENV 
is spread to humans by mosquito bites, primarily by Aedes aegypti, and causes a febrile illness known as dengue 
fever (DF). In some cases, patients can develop a severe and life-threatening form of dengue disease known as 
dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS)10,11. In 2009, the WHO published a re-
classification of the dengue case classification as “dengue with or without warning signs” and “Severe dengue”12. 
Most DHF cases and all DSS cases are reclassified as Severe dengue in this new system.
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DENV has four distinct serotypes, (DENV 1-4) and immunity to each is long-lasting and provides homo-
typic  protection13,14. However, in DENV endemic regions, a patient can experience multiple DENV infections 
in a lifetime. A typical DENV infection is characterized by an incubation period of 4–7 days before fever onset. 
DF is an acute febrile illness that consists of fever, headache, myalgia, retro-orbital pain, nausea and rash. Leu-
kopenia and mild thrombocytopenia are frequently observed in DF  patients15,16. Hemorrhagic manifestations 
such as petechiae, purpura, gingival bleeding and gastrointestinal bleeding are also observed in some  cases17,18. 
The febrile period lasts for 5–7 days before symptoms resolve. At the point when symptoms of febrile illness are 
resolving, some patients may experience severe and life threatening complications such as DHF and  DSS12,19. 
DHF is characterized by high fever, thrombocytopenia and major bleeding (measured by a rise in hematocrit 
levels). An important pathology that differentiates DF from DHF is plasma leakage, where an increase in capillary 
permeability allows the transudate to collect at the pleural and abdominal cavities. Gall bladder wall thickening 
and ascites are also observed in DHF  patients20,21. Without intervention, DHF can lead to circulatory failure, 
resulting in narrow pulse pressure and shock. The prognosis for fatal outcomes in DHF at the stage where shock 
is observed increases from 0.2% to 44%10,22. For DHF diagnosis a patient must meet 4 criteria: fever, hemorrhagic 
manifestations, thrombocytopenia (platelet count, < 100,000 platelets/mm3) and evidence of plasma  leakage11. 
Warning signs defined in the 2009 WHO criteria that are associated with DENV infection include abdominal 
pain, persistent vomiting, fluid accumulation, mucosal bleeding, lethargy, liver enlargement and the observation 
of increasing hematocrit combined with rapidly decreasing platelets. It is recommended that patients admitted 
with warning signs should be strictly observed and that medical intervention be promptly instituted. However, 
Severe dengue is diagnosed when a patient displays any of the following clinical signs: severe plasma leakage 
leading to shock or respiratory distress, severe hemorrhaging, or organ failure. Severe dengue could potentially 
be fatal and, therefore, urgent medical care is  needed12. Warning signs appear late in DENV disease, usually 
around day 5 post-fever onset, making it extremely difficult to predict DHF/DSS or Severe dengue in the early 
acute/febrile phase of disease. Other factors, such as high viremia and high levels of viral secretory protein NS1 
have been suggested to be associated with DHF/DSS, but with conflicting  reports23–32.
We previously reported that elevated serum chymase, a mast cell (MC)-specific protease, is highly predictive 
of DHF in both adult and pediatric dengue patients in Sri Lanka and Indonesia when measured within 3–6 days 
of fever onset (acute phase of disease)33,34. We also observed that chymase was not elevated in non-DENV febrile 
patients, most of which had respiratory infections, compared to healthy  controls35. Chymase is a serine protease 
and angiotensin-converting enzyme that can induce vascular  permeability36. It is released by MCs when they are 
triggered to degranulate, which can be induced in response to DENV binding to the cells through an unknown 
 receptor35 or in response to virus/antibody immune complexes through activating receptors such as FcγRIII or 
FcεRI37. In this prospective study, we examined the association of chymase with signs of vascular leakage in hos-
pitalized pediatric patients. Here, we tested whether elevated chymase is observed in pediatric patients meeting 
the criteria of having DHF or Severe dengue, compared to the patients with DF or mild dengue. Furthermore, 
we hypothesized that chymase levels would be elevated in patients experiencing signs of vascular leakage and 
fluid accumulation, such as pleural effusion and gall bladder wall thickening.
Methods
Recruitment of dengue patients and sample collection. Pediatric dengue patients 5–12 years of age 
were prospectively recruited upon parental consent at the Lady Ridgeway Hospital, Colombo, Sri Lanka. Crite-
ria for recruitment included onset of fever (≥ 38 °C for less than 72 h), hospital admission, and confirmation of 
DENV infection by NS1 antigen test (using the SD Dengue NS1 Ag + Ab Combo Dengue Duo, Standard diag-
nostics inc, South Korea) at the time of recruitment. Patients with thalassemia, hemophilia, heart disease, cancer, 
any bleeding disorder, CKD/any renal disease, and immuno-suppressed subjects were excluded. As we found 
that recruitment was difficult due to the strict entry criteria of 72 h (3 days after onset of fever), we relaxed the 
entry criteria to 96 h (4 days after onset of fever) and expanded the ages recruited to include children < 5 years. 
All NS1 positive DENV infections were confirmed by real time RT-PCR. A total of 84 cases were selected for 
laboratory testing for chymase, based on DENV confirmation and sufficient serum provided to complete the 
required molecular tests, with 45 DF cases and 39 DHF cases as a final diagnosis. Three blood samples were 
taken (1–3 days post fever onset, 4–5 days post fever onset and 6–7 days post fever onset) in BD Vacutainer 
SST tubes. Serum was isolated from these 3 sequential samples for DENV confirmation, quantification of viral 
RNA and chymase ELISA. Serum was isolated within 4 h of blood collection and stored at − 80 °C. Criteria 
for assessing the clinical diagnosis as DF or DHF (according to the 1997 WHO criteria) or as dengue with or 
without warning signs or Severe dengue (according to the 2009 WHO criteria) were recorded in the case report 
forms and were reviewed by multiple study team members who were not involved in the blinded laboratory 
analysis. Study questionnaires were filled by study team members based on patient interviews. Ultrasounds were 
performed as per the hospital standard protocol for dengue management, daily, from the first full day of hospi-
talization. The laboratory and clinical records were transcribed from the case notes of the patients into the case 
report forms by a trained clinician.
Research was designed to be compliant with the Declaration of Helsinki. Ethical approvals were obtained 
from the Institutional Review Boards of Lee Kong Chian School of Medicine, Nanyang Technological University 
(NTU), Singapore, National University of Singapore and the Ethics Review Committee of Faculty of Medicine, 
University of Colombo, Sri Lanka. Written informed consent was given by a parent or guardian of the patient.
Serum chymase quantification.  Human mast cell chymase I (CMA-I) kit (BlueGene Biotech, catalogue 
number E01M0368) was used to measure chymase levels in the patients’ serum by following the manufacturer’s 
instructions. Samples were blinded for chymase ELISA and viral quantification.
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Confirmation and quantification of DENV infection.  Viral RNA was isolated from 140 μl of serum 
using the QIAamp Viral RNA Mini Kit (catalogue number: 52906) according to manufacturer’s instructions. 
PCR primers used to quantitate DENV1-4 from human sera were reference reagents obtained from the US 
Centers for Disease Control (CDC) and Prevention (catalog number: KK0129) and were used following the 
manufacturer’s protocol, according to the published  method38. Invitrogen SuperScript III Platinum One-Step 
qRT-PCR kit (catalog number: 11732088) was also used in combination with the CDC reference reagents as 
instructed by the CDC method. Standard curves for viral quantification were generated using plasmids contain-
ing the DENV sequence of interest for DENV1-4 and viral titers are represented as genome copies per ml. To 
determine primary versus secondary DENV infections, DENV-specific IgM and IgG were measured in the acute 
serum samples. For this, the Panbio Dengue IgG Capture ELISA (Catalog number: 01PE10) and Panbio Dengue 
IgM Capture ELISA (Catalog number: 01PE20), both from PanBio Diagnostics, were used. Primary cases were 
identified as  IgM+IgG− and secondary cases were identified as  IgM+IgG+39.
Data analysis. Demographic statistics were generated using SPSS software (IBM). Prism software was used 
to compare mean chymase levels by 1- or 2-way ANOVAs. SPSS was also used for post-hoc power analysis. 
Results were considered significant at a p value < 0.05. After the selection of samples based on the inclusion cri-
teria and dengue confirmation, no data were excluded. Unblinding and data analysis were performed only after 
all laboratory analyses were completed.
Results
Characteristics of patient cohort and DENV infections.  A total of 91 dengue NS1 positive febrile 
children recruited into the study were confirmed as DENV-positive in subsequent laboratory tests (DENV PCR 
positive) and 84 had provided sufficient serum for completing the test for chymase detection. Study subjects 
were under 12 years of age (Fig. 1a) and were 61% male, 39% female. A majority of DENV cases were sec-
ondary DENV infections, with 62% secondary infections and 38% primary DENV infections (Fig. 1b), deter-
mined by serology. Consistent with the emergence of DENV1 as the dominant epidemic serotype in the region 
since  200940, the predominant serotype responsible for DENV infection in this cohort was DENV1, followed by 
DENV2 and DENV4 (Fig. 1b). Final diagnosis was assessed at the completion of the study based on clinical and 
laboratory assessments and none of the patients included met the case definition for DHF at the time of enroll-
ment. Overall, the rates of DHF in this hospitalized cohort were high, with 46% (n = 39 DHF of n = 84 total) of 
study subjects receiving the final diagnosis of DHF, likely due to the fact that mild disease that did not require 
hospitalization was not represented in the cohort. Importantly, we noted that some DHF patients were recruited 
later in the course of disease compared to DF patients (Fig. 1c). We stratified all analyses based on day post fever 
onset to accurately reflect the kinetics of viremia and serum biomarker levels over time. Three blood samples 
were taken for each patient, with 93% retention for the second sample and 63% retention for the third sample. 
Drop-out was primarily due to recovery from DENV disease and withdrawal from the study after discharge from 
the hospital. There were no DENV-associated deaths in this cohort.
elevated early chymase correlates with severe dengue and DHf. We measured chymase in the 
prospectively obtained serum samples and analyzed stratified based on the day of fever onset, which was deter-
mined by questionnaire. A significant increase in the levels of chymase was observed at day 3 post fever onset for 
the patients whose final diagnosis was DHF compared to a final diagnosis of DF (Fig. 2a). Chymase was elevated 
in the serum of both DF and DHF patients compared to healthy controls (Fig. S1). Viral titers in the serum did 
Figure 1.  Characteristics of DENV infection and recruitment of patients. (a) Age distribution of subjects 
enrolled in the study and confirmed DENV-positive. (b) Chart depicts the proportions of primary and 
secondary DENV cases and the serotypes of DENV that were confirmed by PCR. (c) Histograms depict the 
numbers of patients recruited (frequency) for each day post-fever onset. The x-axis represents the number of 
days between fever onset and patient enrollment for DHF (n = 39) and DF (n = 45) patients. Black lines indicate 
the fitted curves for each histogram.
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Figure 2.  Serum chymase levels are prognostic of DHF and Severe dengue and peak later in Severe dengue patients. (a) Comparisons 
of serum chymase concentrations between DHF and DF patients (defined according to the WHO 1997 criteria), stratified by day post-
fever onset. Chymase levels are elevated in DHF patients compared to DF patients, p = 0.0076, analyzed by 2-way ANOVA for days 3–7. 
(b) Serum virus titers (genome copies per mL of serum), determined by RT-PCR did not differ between DHF and DF patients (defined 
by WHO 1997 criteria). (c) Comparison of percentages of patients meeting the WHO 1997 diagnosis criteria for DHF versus DF, 
WHO 2009 diagnosis criteria for Severe dengue versus DF (with or without clinical warning signs). Those DHF patients that did not 
meet the WHO 2009 criteria for Severe dengue met the criteria for DFWS (n = 15). Some patients that met the 1997 criteria for DF met 
the criteria for DFWS. (n = 8) (d) Overlapping pie charts compare the proportions of DHF/DFWS and DF/DFWS patients displaying 
the warning signs of liver enlargement and clinical fluid accumulation. (e) Comparisons of serum chymase concentrations between 
Severe dengue and DF patients (defined according to the WHO 2009 criteria), stratified by day post-fever onset. (f) Concentrations 
of serum chymase amongst groups divided based on severity according to both 1997 and 2009 criteria for Severe dengue disease. 
Chymase levels in the serum do not distinguish between DHF/Severe and DHF/DFWS groups on day 3 post-fever onset, but chymase 
levels of DHF/Severe patients are significantly elevated over DHF/DF-WS patients on day 5 post fever onset. Comparisons amongst 
groups were performed by ANOVA with Sidak’s multiple comparison test. Error bars represent the SEM and ** indicates p < 0.01.
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not correlate with DHF and were not significantly different between DHF and DF patients at any time points 
tested post fever onset (Fig. 2b). Viremia was reduced on days 5 and 7 compared to day 3 and likely resolving 
(Fig. 2b).
Since 2009, the WHO has recommended classifying dengue disease as Severe dengue, DF with warning signs 
(DFWS), or DF without warning signs (DF no-WS)12. Therefore, although this scheme is not routinely employed 
for clinical assessment in Sri Lanka, we also reclassified our patient cohort following the 2009 guidelines. This 
resulted in 16% of patients in our hospitalized cohort being classified as Severe dengue (Fig. 2c). We also found 
that 29% of total study subjects who experienced DHF, according the 1997 criteria, fell in to the DFWS category 
according to the 2009 criteria (Fig. 2c), while another 15% of patients with a DF diagnosis by the 1997 criteria 
also had at least one warning sign (Fig. 2c). This group of patients with DF/DFWS according to the 1997/2009 
criteria, respectively, had a higher incidence of liver enlargement and a lower incidence of clinical fluid accumu-
lation than the patients falling into the categories of DHF/DFWS (by the 1997 and 2009 criteria, respectively) 
(Fig. 2d). Consistent with the results of analysis using the 1997 classification (Fig. 2a), data reanalysis using 2009 
criteria showed that chymase levels were significantly higher in the sera of Severe dengue patients compared to 
DF patients (Fig. 2e). Since reclassification of patients from the 1997 to 2009 WHO schemes effectively defines 
the less severe DHF patients as DFWS, we compared chymase levels between DHF patients in those two groups 
(DHF/DFWS vs. DHF/Severe by the 1997/2009 classifications). Patients with Severe dengue were not distinguish-
able from patients in the DHF/DFWS category at the early time point of 3 days post-fever onset (Fig. 2f). Yet, 
by day 5 post-fever onset, patients with Severe dengue (DHF/Severe) had significantly higher levels of serum 
chymase compared to patients meeting the criteria for DHF/DFWS diagnosis (Fig. 2f). This suggests that the 
processes that underlie exacerbated severity late in the time course of DENV disease are correlated with high 
chymase levels. Importantly, for both comparisons of DHF versus DF and Severe dengue versus DF (with and 
without warning signs), when chymase levels were analyzed relative to the day of enrollment rather than self-
reported fever onset, significantly elevated chymase was still observed to correlate with severity (Fig. S2). We 
also noted that chymase levels were higher for DF patients in this study, compared to a previous Sri Lankan 
cohort we examined where non-hospitalized patients were also  included33. However, average chymase levels 
for the DF patients (which were all hospitalized prior to recruitment) in this study were similar to the levels 
observed in pediatric patients who displayed signs of bleeding in that prior study (Fig. S3). Also similar to previ-
ous  observations35, we did not observe augmented chymase levels in secondary DENV infection of DF patients, 
but did observe higher chymase levels in secondary DENV patients that were subsequently diagnosed with 
DHF (Fig. S4). These data indicate that Severe disease, defined by multiple objective clinical criteria, is strongly 
associated with elevated serum chymase. Longitudinal assessment of serum chymase concentrations indicates 
that it is elevated throughout the acute disease phase and persists at high levels longer in the serum of the most 
severe patients (Fig. 2).
clinical parameters associated with DHf and their correlation with chymase. Clinical signs and 
laboratory measures of disease, which were defined a priori, were obtained for hospitalized patients throughout 
their stays. Certain clinical parameters were also associated with DHF diagnosis, for example, DHF patients dis-
played higher maximum-recorded venous and capillary hematocrit values compared to DF patients (Fig. 3a,b). 
DHF patients also experienced significantly lower minimum platelet counts over the course of hospitalization 
(Fig.  3c). These hematological perturbations were expected since thrombocytopenia and plasma leakage are 
components of the DHF case definition. DENV patients also may experience narrowing of pulse pressure, 
which is strongly associated with hypovolemia in DHF Grades 3 and 4, or  DSS41. We noted that the minimum 
pulse pressure throughout the patient’s involvement with the study was lower in DHF patients compared to DF 
patients (Fig. 3d). To evaluate whether narrowing of pulse pressure was also associated with elevated chymase 
levels, we compared the serum chymase concentrations between patients with narrow pulse pressure (below 
20 mmHg) and those with pulse pressure > 20 mmHg. Indeed, serum chymase concentrations were significantly 
higher in patients with narrow pulse pressure (Fig. 3e).
To evaluate if any specific DENV warning signs were associated with elevated chymase, chymase levels were 
analyzed in patients who presented with one or more dengue warning sign. Interestingly, chymase levels were 
significantly higher in patients who presented with abdominal pain, fluid accumulation, lethargy, hematocrit 
increase concurrent with sudden platelet drop (hematologic WS) and/or severe leak, compared to the patients 
who did not present any warning signs (Fig. 3f). Chymase was not significantly elevated in DFWS patients dis-
playing the warning signs of vomiting, mucosal bleeding, or liver enlargement compared to DF no-WS patients 
(Fig. 3f). This suggests a link between elevated chymase and DENV disease processes that involve pathologies 
of the vascular system and fluid accumulation.
Higher chymase levels are associated with pleural effusion and gall bladder wall thickening in 
hospitalized dengue patients. Plasma leakage during DHF can result in a life-threatening shock syn-
drome and is a consistent feature of severe dengue disease. Clinical and laboratory assessments indicated an 
association between fluid accumulation and chymase (Fig. 3); therefore, we aimed to confirm this using an inde-
pendent technique to verify fluid accumulation. Some studies suggested that plasma leakage could be detected 
in DHF patients by ultrasound of the chest and abdominal  cavity42,43. Thickening of the gall bladder wall and 
pericardial effusion have also been associated with plasma  leak20,44,45. Therefore, we sought to verify if these were 
also observed in our pediatric cohort and/or correlated with chymase. By ultrasound, the extent of ascites, pleu-
ral effusion, gall bladder wall thickening, perirenal fluid accumulation, pericardial effusion and liver enlarge-
ment were assessed (Fig. 4a–g). For our analysis, we recorded whether these signs were observed by ultrasound 
at any time during the patient’s hospitalization. Indeed, all of these abnormal ultrasound observations were 
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significantly associated with a DHF diagnosis (Fig. 4b–g). Interestingly, we observed that chymase levels were 
higher in patients where pleural effusion and/or gall bladder wall thickening were present, compared to patients 
where those signs were unobserved (Fig. 4h). This, in combination with the association of elevated chymase with 
hypovolemia (Fig. 3e), establishes chymase to be an important early indicator of the clinical fluid accumulation 
that is characteristic of DHF/DSS and Severe dengue.
Discussion
Chymase, which is a vasoactive serine protease produced specifically by MCs, was found in this study to be 
significantly elevated in patients that experienced warning signs and laboratory parameters associated with 
vascular leakage. Prior human studies have indicated that chymase is an efficient biomarker for DHF prognosis 
since the protein levels are increased in the acute-phase serum samples from both adult and pediatric DENV 
cases that subsequently are diagnosed with  DHF33,35. In contrast, virus-derived products such as NS1 or viremia 
have not consistently been shown to be predictive of severe  disease46,47. In support of a mechanistic role for MC-
derived products in DENV-induced vascular leakage, drugs that specifically inhibit MC activation are able to 
experimentally reduce vascular leakage in animal  models35,48. In this prospective study, we aimed to provide more 
information regarding the association of chymase with severe dengue disease. We explored whether chymase 
levels correlate with measures of vascular leakage and clinical warning signs of disease severity. We also provide 
an understanding of chymase concentrations in the sera of hospitalized pediatric patients, longitudinally, and 
compare the ability of chymase to prognosticate both DHF and Severe dengue, according to the 1997 and 2009 
WHO classification schemes. Our analysis showed that chymase was significantly associated with DHF and 
Severe dengue following both the WHO 1997 and 2009 guidelines for dengue classification.
As expected based on multiple studies comparing the two classification  schemes49-51, reclassification of DHF 
patients in our cohort to the 2009 classification scheme resulted in two groups of patients: patients with Severe 
dengue and a subset of the DFWS patients, consistent with the view that the 2009 criteria more stringently define 
severity. Interestingly, while chymase was significantly elevated in the serum samples of patients at the time of 
presentation and predictive of both DHF and Severe dengue, the levels of chymase were similar for DHF/Severe 
patients and DHF/DFWS patients at early time points. These data support the potential utility of chymase as a 
prognostic biomarker of DHF/Severe dengue disease according to multiple classification schemes for disease 
severity. By the later time point of 5 days post-fever onset, DHF/Severe patients showed significantly higher 
levels of serum chymase than DHF/DFWS patients. This time point corresponds to an approximate time in the 
course of disease when fever begins to resolve, warning signs are more likely become apparent and severe disease 
may begin to present. The persistence of chymase in patients with Severe dengue compared to other groups may 
indicate a lack of resolution of disease processes promoting elevated chymase in the most severe patients. Fur-
thermore, it raises the potential that chymase levels can not only be used to prognosticate DHF/Severe disease, 
but also to monitor for the effectiveness of therapeutic interventions.
This study revealed that signs and laboratory measures of vascular leakage, fluid accumulation and hypov-
olemia were strongly linked to elevated chymase. DHF patients displayed higher maximum venous and capillary 
hematocrit values compared to DF patients, as well as reduced platelet counts, as expected according to the case 
definition of DHF. Narrowing of pulse pressure was also significantly associated with DHF and those patients 
with narrow pulse pressure had higher levels of chymase than patients outside of the harmful pulse pressure 
range. Since none of the children in the study had cardiac-related pre-existing conditions and because narrow 
pulse pressure is a measure of dengue  hypovolemia52, it suggests that early elevated chymase levels are linked to 
the subsequent presentation of hypovolemia. While these observations might suggest that chymase could also be 
a therapeutic target for severe DENV, our previous mechanistic studies suggest that its contributions to vascular 
leakage are less important than another protease, tryptase, which is also released during MC  degranulation34, 
emphasizing that a biomarker need not be the most consequential mediator for a mechanism of disease to serve 
as a reliable indicator of disease.
Aside from laboratory measures, the presence of warning signs that are particularly indicative of vascular 
leakage were also linked to elevated chymase, including fluid accumulation, severe leakage and the hematologic 
warning sign of rapid rise in hematocrit concurrent with decreased platelets. Patients displaying the warning signs 
of abdominal pain and lethargy also had significantly higher levels of chymase compared to DF no-WS patients. 
We used ultrasounds to monitor the patients since multiple studies have indicated that DENV patients display 
abnormal ultrasound findings, such as gall bladder wall thickening and pleural  effusion43,53,54. The majority of 
DHF patients displayed at least one abnormal ultrasound finding during the patients’ involvement within the 
study and abnormal ultrasounds were strongly associated with a diagnosis of DHF in this cohort. Significantly 
higher levels of serum chymase were noted in patients experiencing pleural effusion and gall bladder wall 
Figure 3.  Clinical parameters indicative of vascular leak occur in dengue patients and are correlated with 
elevated chymase. The maximum (a) venous and (b) capillary hematocrit values that were recorded any time 
over a patient’s hospitalization and association with the study were higher in DHF patients compared to DF 
patients. (c) Compared to DF patients, DHF patients also had lower minimum platelet counts and (d) lower 
minimum pulse pressure recorded. (e) Elevated chymase is significantly associated with severely narrowed pulse 
pressure (< 20 mmHg). For (a–e) Student’s unpaired T test was used to compare DF versus DHF groups. (f) 
Serum chymase levels were significantly higher for patients with certain categories of warning signs (displayed 
at any time during involvement with the study) compared to patients in the DF no-WS group, as determined by 
1-way ANOVA with Holm-Sidak’s post-test. For abdominal WS n = 24; vomiting n = 8; fluid accumulation n = 22; 
mucosal bleeding n = 3; lethargy n = 9; liver enlargement n = 22; hematologic WS n = 22; and severe leak n = 8. 
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thickening, compared to patients where those signs were unobserved. Thus, ultrasound results support the asso-
ciation of chymase with fluid accumulation. However, liver involvement was not strongly associated with chymase 
levels or MC activation. We noted that the subset of patients that met the diagnostic criteria for DF/DFWS had 
lower levels of chymase compared to DHF/DFWS and a high proportion of liver enlargement observed as a key 
2009 criteria warning sign. Consistent with this, patients with the warning sign of liver enlargement did not have 
higher levels of chymase compared to DF no-WS patients. Furthermore, chymase levels were not significantly 
higher in patients where liver enlargement by ultrasound was observed compared to patients where this was 
unobserved. The liver is a target organ of DENV infection and liver failure can occur as a component of multi-
organ failure associated with  DSS55. Although there are MCs present in the  liver56, chymase levels are very low 
in this  organ57, potentially indicating that liver involvement of DENV is less influenced by MCs.
There are multiple strengths of using this cohort to inform our understanding of the utility of chymase as a 
biomarker for severe DENV disease. First, we confined our analysis to prospectively recruited pediatric confirmed 
DENV patients that were hospitalized, allowing serial collection of serum samples and ultrasound readings and 
identification of warning signs that presented throughout the course of disease. However, we did not recruit 
patients for comparison with other febrile illnesses, which should also be compared to DENV patients in future 
studies. Importantly, chymase may be elevated in other infections that cause MC activation so we think chymase 
should be used for DENV prognosis when disease is highly suspected and confirmed by alternate laboratory tests. 
We also noted that chymase levels were higher on average in this patient cohort compared to a previous study 
we conducted in the same region of Sri  Lanka33. We think that this is likely due to the fact that all of the patients 
studied here were hospitalized, likely leading to the recruitment of patients with more moderate/severe disease. 
Figure 4.  Elevated chymase correlates with observation of pleural effusion and gall bladder thickening in 
hospitalized dengue patients. (a) Patients in the study were given ultrasound exams daily, and observation 
of various indicators of DENV disease and/or fluid accumulation were recorded. Diagram was drawn using 
Adobe Illustrator CC software version 20.1.0. Proportions of patients where (b) ascites, (c) pleural effusion, (d) 
gall bladder thickening, (e) perirenal fluid accumulation, (f) pericardial effusion, or (g) liver enlargement were 
observed by ultrasound at any day of the study are presented for patients meeting the WHO-1997 diagnosis 
criteria of DF versus DHF. For (b–g) DHF patients displayed significantly increased incidence of observed 
abnormalities by ultrasound, as determined by Fisher’s exact test. (**** indicates p < 0.0001). (h) Serum chymase 
levels for patients where specific abnormal ultrasound results were observed versus unobserved were compared 
by 2-way ANOVA with Holm-Sidak’s post-test. * indicates p < 0.05. The observed power was calculated post-hoc 
to be 0.741. Error bars represent the SEM.
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Consistent with this notion, the levels of chymase in DF patients in this study were similar to the average chymase 
levels in DF patients with signs of bleeding that were previously assessed in a prior cohort and the baseline levels 
of healthy donors were also similar to those observed in prior  studies33. We also previously reported that pediatric 
DENV patients had trends towards higher chymase levels during DHF compared to adults, although chymase 
was still prognostic for DHF in  adults33. One limitation of this study was that for some clinical manifestations, 
particularly mucosal bleeding, the numbers of patients experiencing the sign were low. Therefore, further stud-
ies with a larger cohort are needed to verify the lack of association of mucosal bleeding with elevated chymase.
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